KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Revenue (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 15 years of Revenue data on record, last reported at $69.8 million in Q4 2025.

  • For Q4 2025, Revenue rose 21.19% year-over-year to $69.8 million; the TTM value through Dec 2025 reached $294.3 million, up 64.15%, while the annual FY2025 figure was $294.3 million, 64.15% up from the prior year.
  • Revenue reached $69.8 million in Q4 2025 per RIGL's latest filing, roughly flat from $69.5 million in the prior quarter.
  • Across five years, Revenue topped out at $101.7 million in Q2 2025 and bottomed at $16.7 million in Q1 2022.
  • Average Revenue over 5 years is $43.0 million, with a median of $32.8 million recorded in 2022.
  • Peak YoY movement for Revenue: crashed 79.34% in 2022, then surged 176.01% in 2025.
  • A 5-year view of Revenue shows it stood at $20.4 million in 2021, then skyrocketed by 151.25% to $51.3 million in 2022, then crashed by 30.2% to $35.8 million in 2023, then skyrocketed by 60.92% to $57.6 million in 2024, then increased by 21.19% to $69.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $69.8 million in Q4 2025, $69.5 million in Q3 2025, and $101.7 million in Q2 2025.